Flubromazolam, also known as JYI-73, belongs to the class of triazolobenzodiazepines (TBZDs), which are derivatives of benzodiazepines (BZDs). This compound has gained a reputation for its remarkably high potency. Concerns have emerged regarding the safety of substances like clonazolam and flubromazolam, mainly due to their potential to induce profound sedation and amnesia, even at very low oral doses, sometimes as minimal as 0.5 mg. Notably, life-threatening adverse reactions have been documented with doses as low as 3 mg of flubromazolam.

IUPAC name
CAS Number612526-40-6 
PubChem CID21930924
CompTox Dashboard (EPA)DTXSID40620266
Chemical and physical data
Molar mass371.213 g·mol−1

Legal status

In Sweden, Flubromazolam was designated as an illicit substance following seizures by customs and law enforcement agencies, coupled with indications from the EMCDDA of its increasing recreational use.
Flubromazolam has been illegal in Switzerland since December 2015.
United Kingdom:
In the United Kingdom, Flubromazolam was classified as a Class C drug through an amendment to The Misuse of Drugs Act 1971 in May 2017. This reclassification also encompassed several other designer benzodiazepine drugs.
Flubromazolam falls under Schedule 9 according to federal law in Australia.
United States:
In the United States, Flubromazolam is regulated in the state of Virginia. On December 23, 2022, the DEA initiated discussions concerning the temporary placement of Flubromazolam in Schedule I. Subsequently, on July 25, 2023, the DEA issued a pre-print notice, stipulating that Flubromazolam would be temporarily scheduled as a controlled substance under Schedule I from 07/26/2023 to 07/26/2025.


  • What is Flubromazolam?
  • Flubromazolam is a synthetic compound belonging to the benzodiazepine class of drugs. It is known for its sedative and anxiolytic (anxiety-reducing) properties and is sometimes used recreationally.
  • Is Flubromazolam Legal?
  • The legal status of Flubromazolam varies by country and region. It is illegal in some places, while in others, it may be unregulated or subject to control measures.
  • How is Flubromazolam Used?
  • Flubromazolam is typically consumed orally, often in the form of tablets, capsules, or as a powdered substance. Users may swallow, snort, or dissolve it in a liquid for consumption.
  • What Are the Effects of Flubromazolam?
  • Flubromazolam can induce sedation, relaxation, and relief from anxiety. Some users also report memory impairment and amnesia. The effects can vary depending on the dosage and individual sensitivity.
  • What Are the Risks and Side Effects?
  • Flubromazolam, like other benzodiazepines, can lead to drowsiness, dizziness, and impaired coordination. It also has a risk of dependence and withdrawal symptoms. Overdose can lead to serious health complications.
  • Is Flubromazolam Addictive?
  • Yes, benzodiazepines, including Flubromazolam, have the potential for addiction. Prolonged use or misuse can lead to physical and psychological dependence.
  • Can Flubromazolam Be Used Safely?
  • It should only be used under the supervision of a medical professional and according to prescribed dosages. Using Flubromazolam recreationally or without a prescription can be dangerous.
  • What Is the Legal Status of Flubromazolam in My Country?
  • The legal status of Flubromazolam can vary widely. It is essential to check your local laws and regulations to understand their position in your region.
  • Are There Drug Interactions to Be Aware Of?
  • Flubromazolam can interact with other drugs, including alcohol. Combining it with other substances can amplify the sedative effects and increase the risk of adverse reactions.
  • What Should I Do in Case of Overdose or Adverse Reactions?
  • If you suspect an overdose or experience severe adverse effects, seek immediate medical attention. It’s essential to be transparent with healthcare providers about your substance use.
  • Can I Stop Taking Flubromazolam Abruptly?
  • No, abruptly discontinuing Flubromazolam can lead to withdrawal symptoms, including anxiety and seizures. It’s important to taper off the medication under the guidance of a healthcare professional.
  • Is There Support Available for Flubromazolam Dependence?
  • Yes, treatment and support options are available for benzodiazepine dependence. If you or someone you know is struggling with Flubromazolam use, consider seeking help from a medical or addiction treatment facility.


  1. Anvisa (2023-03-31). “Collegiate Board Resolution No. 784 – Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control” [RDC Nº 784 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial] (in Brazilian Portuguese). Published in Diário Oficial da União on 2023-04-04. Archived from the original on 2023-08-03. Retrieved on 2023-08-16.
  2. Cook JM, et al. Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic, and ataxic effects. Patent: US7618958.
  3. Borer R, Gerecke M, Kyburz E (22 October 1986). “Patent EP 0072029 B1 – Triazolobenzazepines, process, and intermediates for their preparation and medicines containing them”. Retrieved on 6 August 2015.
  4. Hester JB, Rudzik AD, Kamdar BV (November 1971). “6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines which have central nervous system depressant activity.” Published in the Journal of Medicinal Chemistry. Volume 14, Issue 11, Pages 1078–81. doi: 10.1021/jm00293a015. PMID 5165540.
  5. “Flubromazolam”. Cayman Chemical. Retrieved on 20 November 2015.
  6. Huppertz LM, Bisel P, Westphal F, Franz F, Auwärter V, Moosmann B (July 2015). “Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites.” Published in Forensic Toxicology. Volume 33, Issue 2, Pages 388–395. doi: 10.1007/s11419-015-0277-6. S2CID 33278305.
  7. Chaslot M, El Balkhi S, Robin T, Morichon J, Picard N, Saint-Marcoux F (June 2016). “Exploration des métabolites de 8 benzodiazépines de synthèse.” Published in Toxicologie Analytique et Clinique. Volume 28, Issue 2, Page S32. doi: 10.1016/j.toxac.2016.03.053.
  8. Pettersson Bergstrand M, Helander A, Hansson T, Beck O (April 2017). “Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.” Published in Drug Testing and Analysis. Volume 9, Issue 4, Pages 640–645. doi: 10.1002/dta.2003. PMID 27366870.
  9. Høiseth G, Tuv SS, Karinen R (November 2016). “Blood concentrations of new designer benzodiazepines in forensic cases.” Published in Forensic Science International. Volume 268, Pages 35–38. doi: 10.1016/j.forsciint.2016.09.006. PMID 27685473.
  10. Manchester KR, Maskell PD, Waters L (March 2018). “Experimental versus theoretical log D7.4, pKa and plasma protein binding values for benzodiazepines appearing as new psychoactive substances.” Published in Drug Testing and Analysis. Volume 10, Issue 8, Pages 1258–1269. doi: 10.1002/dta.2387. PMID 29582576.
  11. Wohlfarth A, Vikingsson S, Roman M, Andersson M, Kugelberg FC, Green H, Kronstrand R (May 2017). “Looking at flubromazolam metabolism from four different angles: Metabolite profiling in human liver microsomes, human hepatocytes, mice, and authentic human urine samples with liquid chromatography high-resolution mass spectrometry.” Published in Forensic Science International. Special Issue on the 54th Annual Meeting of the International Association of Forensic Toxicologists (TIAFT) Brisbane from August 28 to September 1, 2016. Volume 274, Pages 55–63. doi: 10.1016/j.forsciint.2016.10.021. PMID 27863836.
  12. Moosmann B, King LA, Auwärter V (June 2015). “Designer benzodiazepines: A new challenge.” Published in World Psychiatry. Volume 14, Issue 2, Page 248. doi: 10.1002/wps.20236. PMC 4471986. PMID 26043347.
  13. Huppertz LM, Moosmann B, Auwärter V (January 2018). “Flubromazolam – Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine.” Published in Drug Testing and Analysis. Volume 10, Issue 1, Pages 206–211. doi: 10.1002/dta.2203. PMID 28378533.
  14. Łukasik-Głębocka M, Sommerfeld K, Teżyk A, Zielińska-Psuja B, Panieński P, Żaba C (2016). “Flubromazolam–A new life-threatening designer benzodiazepine.” Published in Clinical Toxicology. Volume 54, Issue 1, Pages 66–8. doi: 10.3109/15563650.2015.1112907. PMID 26585557. S2CID 4114360.
  15. “Fler ämnen föreslås bli klassade som narkotika eller hälsofarlig vara” (in Swedish). Published by Folkhälsomyndigheten.
  16. “Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien” (in German). Published by Der Bundesrat.
  17. “The Misuse of Drugs Act 1971 (Amendment) order 2017.” Retrieved on 4 April 2023.
  18. Scheduling proposals referred to the November 2015 meeting of the Advisory Committee on Medicines Scheduling (ACMS#16) – 2.6 Flubromazolam.
  19. “Schedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I.” Published in the Federal Register on 23 December 2022. Retrieved on 4 April 2023.
  20. “Schedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I” (PDF). Published by DEA in the Federal Register on July 25, 2023. Retrieved on 2023-07-25.

Leave a Comment

Your email address will not be published. Required fields are marked *